quartr
STX: Q2 sales rose sequentially as a commercial pivot offset Medicaid losses, driving H1 revenue up 41%
Q2 sales grew 4% sequentially but fell 20% year-over-year due to New York Medicaid changes, prompting a successful pivot to the commercial segment, which saw strong prescription and prescriber growth. H1 revenue rose 41% year-over-year, and profitability was achieved.Based on Shield Therapeutics Pl…